Compared side by side
CagriSema vs amycretin: how they differ
The short answer
Both give the GLP-1 and the amylin signal: CagriSema as two weekly drugs, semaglutide and cagrilintide, and amycretin as one Novo Nordisk peptide that switches on both receptors, as a weekly shot or a daily tablet. Neither is approved: Novo Nordisk filed CagriSema with the FDA in December 2025, and amycretin, now named zenagamtide, has been in phase 3 since February 2026. In its main trial CagriSema averaged about 20% weight loss at 68 weeks, and in a small phase 1b/2a trial weekly amycretin shots took off about 22% at 20 mg and 24% at 60 mg over 36 weeks.
Side by side
| Compared | CagriSema | Amycretin |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Cagrilintide/semaglutide, Cagrilintide-semaglutide, Cagri-Sema, Cagri + Sema | Zenagamtide, NNC0487-0111, Amy |
| What it is | Two weekly drugs in one regimen: cagrilintide, a long-acting version of the fullness hormone amylin, and semaglutide, the GLP-1 drug in Wegovy and Ozempic. | One peptide from Novo Nordisk that gives both the GLP-1 and the amylin signal, the pair CagriSema delivers as two drugs, as a weekly shot or a daily tablet. |
| How it works | Weekly combination of two long-acting hormone analogues: cagrilintide, an amylin analogue that acts on amylin and calcitonin receptors, and semaglutide, a GLP-1 receptor agonist. Amylin and GLP-1 curb appetite through partly different brain pathways, so their effects add up: in REDEFINE 1 the pair lost more weight than either drug alone. Doses are written per component (2.4 mg/2.4 mg is 2.4 mg of each). Not approved: Novo Nordisk filed it with the FDA in December 2025, and a decision is expected in the fourth quarter of 2026. | One peptide that switches on both the GLP-1 receptor and the amylin receptors (and the calcitonin receptor), so it carries the two signals CagriSema gives as two drugs. GLP-1 curbs appetite and slows the stomach; amylin adds fullness after meals. A fatty-acid side chain binds it to albumin in the blood, so a weekly shot lasts. Novo Nordisk is developing it as a weekly injection and as a daily tablet. Investigational, in phase 3 since February 2026. |
| Commonly reported | Strong appetite suppression and early fullness, with nausea, vomiting or constipation through the dose steps. In its main trial people lost about 20% of body weight on average at 68 weeks, more than on semaglutide alone; it is not approved yet. | In trials, strong appetite loss and GI side effects during the step-ups. Now named zenagamtide; in phase 3 and not approved anywhere. |
| Studied range | Research range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation. | Research range: 0.4–60 mg, starting dose 0.2 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | ~1 week for each component (measured in people: cagrilintide 159–195 hours and semaglutide 145–165 hours in a phase 1b trial) | ~88 hours (measured in people: 88.1 h after a single 0.3 mg SubQ dose with normal kidney function; Oldenburg 2026) |
| Route | SubQ injection | SubQ injection |
| Typical run | Studied as an ongoing weekly treatment: 68 to 84 weeks in phase 3. Not approved yet; Novo Nordisk filed for US approval in December 2025. | Used continuously, once weekly, in its trials: up to 36 weeks so far, with doses stepped up every 4 weeks. No trial has tested stopping it. |
| Evidence | Established: clinical trials or FDA-approved use exists | Moderate: animal studies + some human data |
| Common side effects | Nausea, vomiting, diarrhea, constipation, abdominal pain | Nausea, vomiting, diarrhea, decreased appetite |
- Category
- CagriSemaMetabolic & GLP-1
- AmycretinMetabolic & GLP-1
- Also known as
- CagriSemaCagrilintide/semaglutide, Cagrilintide-semaglutide, Cagri-Sema, Cagri + Sema
- AmycretinZenagamtide, NNC0487-0111, Amy
- What it is
- CagriSemaTwo weekly drugs in one regimen: cagrilintide, a long-acting version of the fullness hormone amylin, and semaglutide, the GLP-1 drug in Wegovy and Ozempic.
- AmycretinOne peptide from Novo Nordisk that gives both the GLP-1 and the amylin signal, the pair CagriSema delivers as two drugs, as a weekly shot or a daily tablet.
- How it works
- CagriSemaWeekly combination of two long-acting hormone analogues: cagrilintide, an amylin analogue that acts on amylin and calcitonin receptors, and semaglutide, a GLP-1 receptor agonist. Amylin and GLP-1 curb appetite through partly different brain pathways, so their effects add up: in REDEFINE 1 the pair lost more weight than either drug alone. Doses are written per component (2.4 mg/2.4 mg is 2.4 mg of each). Not approved: Novo Nordisk filed it with the FDA in December 2025, and a decision is expected in the fourth quarter of 2026.
- AmycretinOne peptide that switches on both the GLP-1 receptor and the amylin receptors (and the calcitonin receptor), so it carries the two signals CagriSema gives as two drugs. GLP-1 curbs appetite and slows the stomach; amylin adds fullness after meals. A fatty-acid side chain binds it to albumin in the blood, so a weekly shot lasts. Novo Nordisk is developing it as a weekly injection and as a daily tablet. Investigational, in phase 3 since February 2026.
- Commonly reported
- CagriSemaStrong appetite suppression and early fullness, with nausea, vomiting or constipation through the dose steps. In its main trial people lost about 20% of body weight on average at 68 weeks, more than on semaglutide alone; it is not approved yet.
- AmycretinIn trials, strong appetite loss and GI side effects during the step-ups. Now named zenagamtide; in phase 3 and not approved anywhere.
- Studied range
- CagriSemaResearch range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation.
- AmycretinResearch range: 0.4–60 mg, starting dose 0.2 mg. Studied in research — not a recommendation.
- How often
- CagriSemaWeekly
- AmycretinWeekly
- Half-life
- CagriSema~1 week for each component (measured in people: cagrilintide 159–195 hours and semaglutide 145–165 hours in a phase 1b trial)
- Amycretin~88 hours (measured in people: 88.1 h after a single 0.3 mg SubQ dose with normal kidney function; Oldenburg 2026)
- Route
- CagriSemaSubQ injection
- AmycretinSubQ injection
- Typical run
- CagriSemaStudied as an ongoing weekly treatment: 68 to 84 weeks in phase 3. Not approved yet; Novo Nordisk filed for US approval in December 2025.
- AmycretinUsed continuously, once weekly, in its trials: up to 36 weeks so far, with doses stepped up every 4 weeks. No trial has tested stopping it.
- Evidence
- CagriSemaEstablished: clinical trials or FDA-approved use exists
- AmycretinModerate: animal studies + some human data
- Common side effects
- CagriSemaNausea, vomiting, diarrhea, constipation, abdominal pain
- AmycretinNausea, vomiting, diarrhea, decreased appetite
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
CagriSema
- Day 1–28 · 0.25 mg The 0.25 mg start
- Day 29–364 · 0.5 mg 0.5 mg of each
- Day 57–364 · 1 mg 1 mg of each, halfway up
- Day 85–364 · 1.7 mg 1.7 mg of each, one step from the top
- Day 113+ · 2.4 mg 2.4 mg/2.4 mg, the maintenance dose
Amycretin
- Day 1–28 A very low start
- Day 57–140 · 1.25 mg The lowest dose tested for weight
- Day 85–252 With type 2 diabetes
- Day 113–196 · 5 mg Five milligrams
- Day 169–252 · 20 mg Twenty milligrams
- Day 253+ A long-term medicine, not a course
Questions people ask
How long do CagriSema and amycretin last?
The half-life of CagriSema is ~1 week for each component (measured in people: cagrilintide 159–195 hours and semaglutide 145–165 hours in a phase 1b trial). The half-life of amycretin is ~88 hours (measured in people: 88.1 h after a single 0.3 mg SubQ dose with normal kidney function; Oldenburg 2026).
How often are CagriSema and amycretin taken?
CagriSema: weekly. Route: SubQ injection. Amycretin: weekly. Route: SubQ injection.
How are CagriSema and amycretin dosed in research?
The research range for CagriSema is 0.25–2.4 mg, with a 0.25 mg starting dose. The research range for amycretin is 0.4–60 mg, with a 0.2 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of CagriSema and amycretin?
For CagriSema, the library lists: nausea, vomiting, diarrhea, constipation, abdominal pain. For amycretin: nausea, vomiting, diarrhea, decreased appetite.